Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Signal Twitter WhatsApp

Tracy Weber

Senior Editor

Photo of Tracy Weber

Tracy Weber is a senior editor at ProPublica, previously a senior reporter covering health care issues.

In collaboration with Charles Ornstein, Weber was a lead reporter on a series of articles in the Los Angeles Times titled “The Troubles at King/Drew” hospital that won the Pulitzer Prize for public service, the Robert F. Kennedy Journalism Award and the Sigma Delta Chi Award for public service in 2005. Her ProPublica series, with Charles Ornstein, “When Caregivers Harm: California’s Unwatched Nurses” was a finalist for a 2010 Pulitzer Prize for public service.

Weber reported for the Los Angeles Times from 1994 to 1999 and again beginning in 2003. Previous to her prize-winning collaborations with Ornstein, Weber spent a year reporting from inside California’s juvenile court system, prompting reforms in state law. Earlier in her career she reported for the Los Angeles Herald Examiner and the Orange County Register.

Troubled Health-Care Staffing Chain Settles With Government for $150 Million

Maxim Healthcare Services, Inc. had been accused of submitting false bills to federal and state health programs. An earlier ProPublica investigation found that the company had hired several nurses despite a history of problems.

News Reports Cite Drop in Physician Speaking Fees

Regional newspapers that analyzed ProPublica's Dollars for Docs data say drug company payments to physician speakers have declined in their states, suggesting that new restrictions and publicity are making an impact.

Patients Deserve to Know What Drug Companies Pay Their Doctor

ProPublica's newly updated Dollars for Docs database offers a glimpse of what patients can expect in 2013, when all drug and medical-device companies must report to the federal government what they pay doctors to help market their products.

Piercing the Veil, More Drug Companies Reveal Payments to Doctors

An update of ProPublica's Dollars for Docs database includes more than $760 million in payments from 12 pharmaceutical companies to physicians and other health-care providers for consulting, speaking, research and expenses.

Dollars for Docs

Has Your Doctor Received Drug Company Money?

With Our Dollars for Docs Update Coming, Drug Companies Defend 'Interactions' With Physicians

As ProPublica gets ready to refresh its Dollars for Docs database listing payments from drug companies to hundreds of thousands of doctors, the Pharmaceutical Research and Manufacturers of America says paid physician speakers play a critical role in improving patient care.

Medical Schools Plug Holes in Conflict-of-Interest Policies

Reacting to ProPublica's Dollars for Docs coverage, Stanford and other schools discipline doctors, rewrite policies and increase scrutiny of drug-industry ties.

How Much Money Do Groups Receive From Industry?

In a response to a request from Sen. Charles Grassley, R-Iowa, 33 professional associations and health advocacy groups listed their payments from the pharmaceutical, medical device and insurance industries. They also detailed the relationships that the groups’ executives and board members had with the same companies.

Heart Society’s Tip Sheets Fail To Mention Risks

The Heart Rhythm Society says the financial support it receives from drug and medical-device makers plays no role in its advocacy for certain treatments. Information sheets published by the group do not mention potential risks from implanted defibrillators or cardiac catheter ablation.

Financial Ties Bind Medical Societies to Drug and Device Makers

Professional groups like the Heart Rhythm Society write guidelines on treatments and the use of medical devices, but researchers say their acceptance of sponsorships and grants from drug and device makers poses a conflict of interest that many patients never consider.

The Heart Rhythm Society Responds to ProPublica’s Questions

Reporters Charles Ornstein and Tracy Weber sent the Heart Rhythm Society a set of questions about potential conflicts of interest regarding the group’s acceptance of drug and device industry marketing money. The responses below were provided by the group’s president, Dr. Douglas L. Packer, and president-elect, Dr. Bruce L. Wilkoff.

Medical Groups Shy About Detailing Industry Financial Support

Sen. Charles Grassley asked 33 health organizations who their corporate backers are, and responses show that some get half their income from the medical industry. Critics say public disclosure of industry ties is needed.

Dollars for Docs Adds Payouts from HIV Drug Maker

ViiV Healthcare, which specializes in HIV medications, disclosed paying $3.4 million in speaking and consulting fees to doctors during the first three quarters of 2010. It becomes the eighth company in Dollars for Docs database.

Dollars for Docs Sparks Policy Rewrite at Colorado Teaching Hospitals

The University of Colorado Denver and its affiliated teaching hospitals have launched an overhaul of conflict of interest policies after a ProPublica database revealed extensive ties between its faculty and pharmaceutical companies.

Dollars for Docs Payments Approach $300 Million

ProPublica has added another $13 million in payments to our Dollars for Docs database of drug-company spending on doctors and other health professionals. That brings the total to nearly $295 million.

Drug Companies Retain Tight Control of Physicians’ Presentations

Drug companies keep strict control of materials doctors use in paid presentations about pharmaceuticals. The companies say this ensures that speakers comply with U.S. FDA regulations.

Med Schools Flunk at Keeping Faculty Off Pharma Speaking Circuit

Top U.S. medical schools and teaching hospitals are failing to adequately enforce policies that prohibit or restrict faculty physicians from being paid by drug companies to give promotional speeches about their products.

In Minnesota, Drug Company Reports of Payments to Doctors Arrive Riddled With Mistakes

A new federal plan will require drug and medical device companies to report all payments to U.S. physicians in 2013. The danger? As Minnesota discovered, some information submitted may not be accurate.

Drug Firms Say They'll Take Closer Look at the Docs They Pay

Seven drug companies paid $7.1 million to 292 doctors who faced disciplinary action or other regulatory sanctions, ProPublica found. Several companies say they may take steps to tighten screening procedures for physicians who are paid as speakers or for other activities promoting prescription drugs.

Follow ProPublica

Our Latest Stories

Current site Current page